Scarica l'app Stockscreener
38.12
0.08%
0.03
Dopo l'orario di chiusura:
38.12
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Will Dianthus Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Low Risk Profit Maximizing Plans - ulpravda.ru
Why Dianthus Therapeutics Inc. stock could outperform in 2025Portfolio Update Summary & Real-Time Volume Triggers - ulpravda.ru
Can Dianthus Therapeutics Inc. stock hit record highs againJuly 2025 Sentiment & Risk Managed Investment Entry Signals - ulpravda.ru
DNTH: Analyst Raises Price Target to $63, Maintains Buy Rating | - GuruFocus
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00 - MarketBeat
Market Outlook: What technical charts say about Dianthus Therapeutics Inc. stock2025 Analyst Calls & Long-Term Investment Growth Plans - ulpravda.ru
Cash per share of Dianthus Therapeutics, Inc. – LS:A3ERZ4 - TradingView — Track All Markets
San Gabriel Valley Tribune - FinancialContent
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run - The Motley Fool
Laser Focus WorldDianthus Therapeutics, Inc.Common Stock (Nasdaq:DNTH) Stock Quote - FinancialContent
Why Dianthus Therapeutics Inc. (87E) stock fits value portfolios2026 world cup usa national team quarterfinals goalkeepers high defensive line odds analysis breakdown - ulpravda.ru
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Dianthus Therapeutics Enters Oversold Territory (DNTH) - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech targeting severe autoimmune diseases to present at JPM event - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.3% – Here’s Why - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3%What's Next? - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat
ETF Watch: Why Dianthus Therapeutics Inc stock could outperform in 2025Market Movement Recap & AI Enhanced Execution Alerts - moha.gov.vn
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047 - MSN
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial for LBL-047 (DNTH212), a Bifunctional Fusion Protein Targeting Autoimmune Disorders - Quiver Quantitative
Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus - TradingView — Track All Markets
New lupus drug test begins, aiming for simple self-injections every month - Stock Titan
Leads Biolabs and Dianthus dose first subject in LBL-047 trial - Investing.com Canada
Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Earnings Notes - Trefis
How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockPortfolio Return Report & High Conviction Investment Ideas - Улправда
Aug Closing: How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockJuly 2025 Recap & Daily Profit Focused Screening - Улправда
Wall Street Recap: Is Dianthus Therapeutics Inc. stock overvalued by current metricsCPI Data & AI Enhanced Trading Signals - Улправда
First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Bain Capital Life Sciences Investors LLC Has $46.24 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
What drives Dianthus Therapeutics Inc 87E stock priceLow Risk Investment Ideas & Low Cost Trading Tips - earlytimes.in
EBIT per share of Dianthus Therapeutics, Inc. – GETTEX:87E - TradingView — Track All Markets
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat
Dianthus Therapeutics CFO & CBO Ryan Savitz Sells 20,000 Shares - TradingView — Track All Markets
CFO Savitz Sells 20,000 ($903.6K) Of Dianthus Therapeutics Inc [DNTH] - TradingView
Ashland, Bitdeer, and More Stocks See Action From Activist Investors - Barron's
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighHere's Why - MarketBeat
Nothing is Better Than Dianthus Therapeutics Inc (DNTH) stock at the moment - setenews.com
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 45.0 USD By Investing.com - Investing.com Nigeria
Can Dianthus Therapeutics Inc. (87E) stock sustain breakout momentum2025 AllTime Highs & Detailed Earnings Play Alerts - Newser
CFO Savitz Files To Sell 20,000 Of Dianthus Therapeutics Inc [DNTH] - TradingView — Track All Markets
Is Dianthus Therapeutics Inc. (87E) stock a contrarian opportunityWeekly Loss Report & Real-Time Volume Analysis - Newser
Dianthus Therapeutics stock hits 52-week high at 45.0 USD - Investing.com
Can Dianthus Therapeutics Inc. (87E) stock deliver double digit returnsPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Will Dianthus Therapeutics Inc. (87E) stock outperform value peersTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat
CapEx per share of Dianthus Therapeutics, Inc. – TRADEGATE:87E - TradingView
Dianthus Therapeutics (DNTH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
DNTH: Advancing two autoimmune therapies with strong clinical data and $525M cash runway - TradingView
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):